Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Net Cash Flow (2016 - 2025)

Protalix BioTherapeutics has reported Net Cash Flow over the past 16 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $1.1 million for Q4 2025, up 113.81% from a year ago — trailing twelve months through Dec 2025 was -$5.0 million (down 130.46% YoY), and the annual figure for FY2025 was -$5.0 million, down 29.08%.
  • Net Cash Flow for Q4 2025 was $1.1 million at Protalix BioTherapeutics, up from -$4.2 million in the prior quarter.
  • Over the last five years, Net Cash Flow for PLX hit a ceiling of $28.3 million in Q4 2021 and a floor of -$27.8 million in Q3 2023.
  • Median Net Cash Flow over the past 5 years was $385000.0 (2025), compared with a mean of $719950.0.
  • Biggest five-year swings in Net Cash Flow: surged 502.96% in 2021 and later crashed 1483.83% in 2022.
  • Protalix BioTherapeutics' Net Cash Flow stood at $28.3 million in 2021, then crashed by 77.33% to $6.4 million in 2022, then crashed by 49.31% to $3.3 million in 2023, then crashed by 336.8% to -$7.7 million in 2024, then soared by 113.81% to $1.1 million in 2025.
  • The last three reported values for Net Cash Flow were $1.1 million (Q4 2025), -$4.2 million (Q3 2025), and -$1.6 million (Q2 2025) per Business Quant data.